Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Total Liabilities data on file, last reported at $748.6 million in Q4 2025.

• Total Liabilities for Q4 2025 came in at $748.6 million, up 20.73% year-over-year; the trailing twelve-month figure through Dec 2025 was $748.6 million (up 20.73% YoY), and the FY2025 annual result was $748.6 million, up 27.44% from the prior year.
• Total Liabilities improved to $748.6 million in Q4 2025 per TLX's latest filing, from $620.1 million in the prior quarter.
• Over five years, Total Liabilities peaked at $748.6 million in Q4 2025 and troughed at $167.3 million in Q4 2023.
• A 3-year average of $512.0 million and a median of $620.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 270.57% in 2024, then advanced 20.73% in 2025.
• A 3-year view of Total Liabilities shows it stood at $167.3 million in 2023, then surged by 270.57% to $620.1 million in 2024, then advanced by 20.73% to $748.6 million in 2025.
• Business Quant data shows TLX's Total Liabilities at $748.6 million in Q4 2025, $620.1 million in Q4 2024, and $167.3 million in Q4 2023.